Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Pfizer CDR CAD Hedged | NEO:PFE | NEO | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.03 | 0.26% | 11.63 | 11.61 | 11.64 | 11.69 | 11.51 | 11.57 | 47,359 | 20:41:13 |
From Nov 2023 to Nov 2024
By Ben Glickman
Merck & Co., Pfizer and Astellas Pharma have received approval from the U.S. Food and Drug Administration for using Keytruda in combination with Padcev to treat a form of bladder cancer.
Merck announced the FDA approval late Friday. The decision was based on the results from a trial conducted in collaboration with Seagen, now owned by Pfizer, and Astellas.
The new approval is specifically for Keytruda, Merck's immunotherapy drug, and Padcev, Seagen and Astellas' antibody-drug conjugate, in treating adult patients with locally advanced or metastatic urothelial cancer.
Merck said the approval was nearly five months prior to the FDA's target date.
Merck said the trial showed a statistically significant improvement in its major efficacy endpoints of overall survival and progression-free survival when compared to platinum-based chemotherapy.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 15, 2023 17:38 ET (22:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Pfizer CDR CAD Hedged Chart |
1 Month Pfizer CDR CAD Hedged Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
